TEM1 Antibody

What is TEM1 and why is it significant in cancer research?

TEM1 (Tumor Endothelial Marker-1), also known as CD248 or Endosialin, is a human protein encoded by the CD248 gene, comprising 757 amino acid residues. It has emerged as a significant tumor vascular marker with considerable therapeutic and diagnostic potential . TEM1 is implicated in critical processes including neo-angiogenesis, vascular cell adhesion and migration, and tumor progression . Its significance stems from several key characteristics: it is highly expressed in tumor vasculature of various cancers but shows minimal expression in normal adult tissues; in breast cancer, TEM1 overexpression correlates with lymph node metastasis, recurrence, and mortality; and in ovarian cancer, increased TEM1 expression appears in endothelial cells and vasculature-associated leukocytes within the tumor microenvironment . Unlike cancer cells, vascular markers like TEM1 exhibit lower mutation rates, making them attractive therapeutic targets .

What are the common applications for TEM1 antibodies in research settings?

TEM1 antibodies serve multiple research applications based on their specific characteristics and formulations:

Many commercially available TEM1 antibodies demonstrate reactivity across human, mouse, and rat species, enabling translational research across different model systems . When selecting an antibody for a specific application, researchers should verify the validation data for their intended use case.

How do I validate the specificity of a TEM1 antibody for my research?

Validating TEM1 antibody specificity requires a multi-step approach:

• Positive and negative controls: Use cell lines with known TEM1 expression profiles. MS1 (Mile-Sven1) endothelial cells modified to express human TEM1 can serve as a positive control, while unmodified MS1 cells serve as negative controls .

• Concentration-dependent binding assay: Perform a live-cell ELISA using varying antibody concentrations (0.1-10 nM range) on both TEM1-positive and TEM1-negative cells. Specific binding should be detectable at concentrations as low as 0.1 nM, with minimal non-specific binding below 10 nM .

• Western blot verification: Confirm the antibody detects a protein of the expected molecular weight (~157 kDa for full-length human TEM1).

• Knockout/knockdown validation: Compare antibody binding in TEM1 knockout models versus wild-type tissues. Studies have shown that TEM1 knockout mice are viable with no impaired normal biological processes, making them excellent negative controls .

• Cross-reactivity testing: If your research involves multiple species, verify the antibody's cross-reactivity with TEM1 from each relevant species, as some antibodies (like scFv78 derivatives) bind to both human and mouse TEM1 .

How can TEM1 antibodies be optimized for in vivo imaging applications?

Optimizing TEM1 antibodies for in vivo imaging requires careful consideration of several parameters:

• Antibody format selection: While single-chain variable fragments (scFvs) offer good tissue penetration, their monovalency often limits functional efficacy. Fc-fusion proteins combining scFvs with immunoglobulin Fc domains typically demonstrate improved pharmacokinetic profiles. For example, 78Fc (a fusion protein of scFv78 with human IgG1 Fc) exhibits sub-nanomolar affinity for TEM1, approximately 15-fold higher than the original scFv78 .

• Avidity optimization: Multivalent formats significantly enhance binding strength. In live-cell ELISA assays, bivalent Fc-fusion proteins demonstrate lower Kd values compared to monovalent scFvs, with 78Fc showing the highest avidity among tested derivatives .

• Stability engineering: For in vivo applications, thermal and serum stability are crucial. Successful antibody derivatives like 78Fc demonstrate excellent stability in physiological conditions, with minimal degradation in mouse serum after 72 hours at 37°C .

• Labeling strategy: For near-infrared (NIR) optical imaging, select fluorophores with emission wavelengths in the 700-900 nm range to minimize tissue autofluorescence and maximize penetration depth. Conjugation should be performed using site-specific methods that preserve antibody binding capacity .

• Codon optimization: For recombinant antibody production, improve the Homo sapiens Codon Adaptation Index (CAI) score of the coding sequence (optimal score ≥0.96) to enhance expression yield and purification efficiency .

What are the key considerations when designing experiments to assess TEM1 expression in tumor vasculature?

Designing robust experiments to assess TEM1 expression in tumor vasculature requires attention to several critical factors:

• Sample selection and processing:

  • Include both tumor and matched normal tissues from the same patient

  • Use fresh-frozen samples when possible to preserve antigen integrity

  • For FFPE tissues, optimize antigen retrieval protocols specifically for TEM1

• Co-staining strategies:

  • Combine TEM1 staining with established endothelial markers (CD31, CD34) to distinguish vascular expression

  • Include pericyte markers (α-SMA, PDGFR-β) to differentiate between endothelial and pericyte TEM1 expression

  • Use tumor cell markers relevant to your cancer type to assess potential non-vascular TEM1 expression

• Quantification methods:

  • Employ digital image analysis to quantify vessel density and TEM1 expression intensity

  • Calculate the percentage of TEM1-positive vessels among all CD31+ vessels

  • Assess the correlation between TEM1 expression and clinical parameters (stage, grade, patient outcomes)

• Controls and validation:

  • Include tissues known to express TEM1 (developing embryonic tissues) as positive controls

  • Use TEM1-knockout or TEM1-negative cell lines as negative controls

  • Validate antibody specificity using multiple antibody clones targeting different TEM1 epitopes

• Expression heterogeneity assessment:

  • Sample multiple tumor regions to account for intra-tumoral heterogeneity

  • Compare primary tumors with metastatic sites when available

How do different TEM1 antibody formats compare in their binding kinetics and tissue penetration profiles?

Different TEM1 antibody formats exhibit distinct binding kinetics and tissue penetration characteristics, which significantly impact their research applications:

Research has demonstrated that fusion proteins combining scFv78 with different domain components from human IgG1 Fc demonstrate significantly improved binding characteristics compared to the original scFv78. Live-cell ELISA assays using MS1 cells expressing human TEM1 showed that while all tested formats reach comparable Bmax (maximum binding capacity), Fc-fusion constructs exhibited substantially lower Kd values, indicating higher avidity. Specifically, 78Fc demonstrated approximately 15-fold higher avidity than the original scFv78 .

The improved pharmacokinetic profiles of Fc-containing fusion proteins result from:

• Slower renal clearance due to increased molecular size

• Enhanced interaction with salvage Fc receptors

• Simplified purification through protein-G/A affinity chromatography

What optimization strategies can improve TEM1 antibody performance in immunohistochemistry?

Optimizing TEM1 antibody performance for immunohistochemistry requires systematic adjustment of several parameters:

• Antigen retrieval:

  • Test multiple retrieval methods: citrate buffer (pH 6.0), EDTA buffer (pH 9.0), and enzymatic retrieval

  • Optimize retrieval time and temperature (typically 95-100°C for 10-30 minutes)

  • For difficult samples, consider dual retrieval methods (heat followed by enzymatic treatment)

• Antibody concentration optimization:

  • Perform titration experiments using a range of concentrations (typically 0.1-10 μg/ml)

  • Test on both positive and negative control tissues to determine optimal signal-to-noise ratio

  • Consider longer incubation times at lower concentrations for reduced background

• Detection system selection:

  • For low expression levels, utilize amplification systems (polymer-based, tyramide signal amplification)

  • For co-localization studies, select fluorescent secondary antibodies with minimal spectral overlap

  • When quantifying expression, ensure the detection system provides linear signal response

• Blocking strategy refinement:

  • Use species-matched serum (5-10%) combined with BSA (1-3%)

  • Add detergent (0.1-0.3% Triton X-100) to reduce non-specific membrane binding

  • Consider specialized blocking reagents for tissues with high endogenous biotin or peroxidase

• Sample preparation considerations:

  • Fresh samples preserved in optimal fixative (typically 10% neutral buffered formalin for 24h)

  • Consistent section thickness (4-5 μm recommended)

  • Attention to storage conditions of cut sections (minimize antigen degradation)

Each optimization step should be systematically documented and validated across multiple tissue samples to ensure reproducibility.

How can researchers design experiments to distinguish between TEM1 expression in tumor cells versus tumor vasculature?

Distinguishing TEM1 expression between tumor cells and vascular components requires carefully designed experimental approaches:

• Multi-color immunofluorescence strategy:

  • Implement triple staining with:

    • Anti-TEM1 antibody

    • Endothelial marker (CD31/CD34)

    • Tumor cell-specific marker (depends on cancer type)

  • Use confocal microscopy for high-resolution co-localization analysis

  • Quantify percentage of TEM1 expression in each cellular compartment

• Laser capture microdissection approach:

  • Identify and isolate tumor cell nests versus vascular structures using guide stains

  • Extract RNA/protein from separately captured cell populations

  • Perform qRT-PCR or Western blot analysis for TEM1 expression in each compartment

  • Compare expression levels using appropriate housekeeping genes/proteins

• Single-cell analysis techniques:

  • Disaggregate tumor tissues into single-cell suspensions

  • Perform flow cytometry using combinations of:

    • Anti-TEM1 antibody

    • Endothelial markers (CD31, CD144)

    • Tumor cell markers (EpCAM, cancer-specific markers)

  • Sort TEM1-positive populations and characterize their cellular identity

  • Alternatively, use single-cell RNA sequencing to create comprehensive expression profiles

• In situ hybridization combined with immunohistochemistry:

  • Perform TEM1 mRNA detection using RNAscope or similar in situ hybridization technique

  • Follow with immunohistochemistry for cell-type specific markers

  • This approach distinguishes cells actively producing TEM1 mRNA versus those potentially binding TEM1 protein

Research has shown that while TEM1 expression is predominantly found in tumor vasculature of carcinomas, it can also be upregulated in the tumor cells themselves in sarcomas . Therefore, cancer type-specific considerations are essential when designing these experiments.

What methods are most effective for measuring TEM1 antibody binding affinity and selectivity?

Multiple complementary approaches should be employed to comprehensively assess TEM1 antibody binding characteristics:

• Surface Plasmon Resonance (SPR):

  • Provides real-time binding kinetics (kon and koff rates)

  • Enables calculation of equilibrium dissociation constant (KD)

  • Compare binding to recombinant human and mouse TEM1 to assess cross-reactivity

  • Test binding to potential off-target proteins with structural similarity

• Live-cell ELISA:

  • Use cells with defined TEM1 expression levels (e.g., MS1 cells engineered to express human TEM1)

  • Perform concentration gradients to generate binding curves

  • Calculate apparent Kd values (as demonstrated with scFv78 derivatives)

  • Include negative control cells to assess non-specific binding

• Bio-Layer Interferometry (BLI):

  • Alternative to SPR for kinetic measurements

  • Particularly useful for higher-throughput screening of multiple antibody candidates

  • Can be performed using crude samples without extensive purification

• Flow Cytometry Titration:

  • Assess binding to native TEM1 in its cellular context

  • Generate mean fluorescence intensity curves at different antibody concentrations

  • Compare binding to cell lines with varying TEM1 expression levels

  • Analyze competition with known TEM1 ligands or other anti-TEM1 antibodies

• Immunohistochemistry Panel:

  • Test staining patterns across multiple tissue types (tumor vs. normal)

  • Quantify staining intensity and distribution

  • Compare with validated TEM1 antibodies

  • Assess correlation between staining patterns and expected TEM1 biology

For the most comprehensive assessment, researchers should calculate and compare multiple parameters including Kd/KD values, Bmax (maximum binding capacity), specificity ratios (target vs. non-target binding), and tissue distribution patterns.

How are TEM1 antibodies being developed for immuno-imaging applications?

TEM1 antibodies are being strategically engineered for immuno-imaging through several innovative approaches:

• Format optimization and engineering:

  • Development of multivalent Fc-fusion proteins from high-affinity single chain antibodies (scFvs)

  • Creation of fusion proteins like 78Fc that maintain high avidity while exhibiting favorable pharmacokinetics

  • Engineering for minimal binding to normal organs with low TEM1 expression

• Near-infrared (NIR) optical imaging applications:

  • Conjugation of TEM1 antibodies with NIR fluorophores

  • Development of tracers that can provide real-time, tomographic information without radioactivity exposure

  • Validation in preclinical models, demonstrating ability to distinguish TEM1-expressing tumor grafts from normal organs

• Positron Emission Tomography (PET) approaches:

  • Radiolabeling of TEM1-specific antibodies (e.g., MORAb-004) for immuno-PET imaging

  • Biodistribution studies showing specific localization to TEM1-positive tumors

  • Exploration of various radioisotopes to optimize imaging parameters

• Multimodal imaging development:

  • Creation of dual-labeled antibodies combining nuclear and optical imaging capabilities

  • Integration of TEM1 targeting with other tumor markers for comprehensive tumor visualization

  • Development of theranostic approaches that combine imaging with therapeutic potential

Research has shown that 78Fc-based NIR tracers perform well in distinguishing both mouse and human TEM1-expressing tumor grafts from normal organs and control grafts in vivo, supporting their further development for clinical applications .

What experimental models are most appropriate for testing TEM1 antibody specificity and efficacy?

Selecting appropriate experimental models for TEM1 antibody evaluation requires consideration of several factors:

• Cell line selection:

  • Engineered cell lines with controlled TEM1 expression:

    • MS1 endothelial cells modified to express human TEM1 at defined levels

    • Paired control lines (parental MS1) for negative controls

  • Naturally TEM1-expressing cell lines:

    • Sarcoma cell lines with endogenous TEM1 expression

    • Primary endothelial cells isolated from tumor tissue

• Animal models:

  • Xenograft models expressing either mouse or human TEM1

  • Spontaneous tumor models where mouse TEM1 is naturally upregulated

  • TEM1 knockout mice as critical negative controls

  • Patient-derived xenografts (PDXs) to better represent human tumor heterogeneity

• 3D in vitro models:

  • Co-culture spheroids containing endothelial cells and tumor cells

  • Organ-on-chip platforms incorporating tumor vasculature

  • Extracellular matrix-embedded cultures to simulate tumor microenvironment

• Ex vivo human tissue analysis:

  • Fresh tumor slices maintained in short-term culture

  • Comparison across multiple cancer types with varying TEM1 expression patterns

  • Matched normal tissues as essential controls

When selecting models, researchers should consider whether they aim to study TEM1 in the vasculature (carcinomas) or in tumor cells themselves (sarcomas) . Additionally, since some antibodies like scFv78 derivatives bind to both human and mouse TEM1, they enable direct translation between mouse models and human applications .

How can researchers quantify TEM1 expression levels across different tumor types and correlate with potential therapeutic response?

Developing standardized approaches to quantify TEM1 expression and predict therapeutic responses requires systematic methodology:

• Comprehensive tissue microarray analysis:

  • Create arrays containing multiple tumor types and matched normal tissues

  • Perform standardized IHC with validated TEM1 antibodies

  • Develop scoring system incorporating:

    • Staining intensity (0-3+ scale)

    • Percentage of positive cells or vessels

    • Compartment-specific expression (vascular vs. tumor cell)

  • Calculate H-scores or other composite metrics

• Quantitative expression profiling:

  • RNA-seq analysis across tumor panels

  • qRT-PCR with validated primer sets for TEM1

  • Normalization against appropriate housekeeping genes

  • Protein quantification via quantitative immunoblotting or mass spectrometry

• Imaging biomarker development:

  • Standardized protocols for TEM1-targeted immuno-imaging

  • Quantitative metrics:

    • Tumor-to-background ratios

    • Standardized uptake values (for PET imaging)

    • Spatial heterogeneity indices

  • Correlation with histopathological TEM1 assessment

• Response prediction markers:

  • In vitro sensitivity assays using TEM1-targeted therapeutics

  • Correlation of baseline TEM1 expression with treatment outcomes

  • Identification of companion biomarkers that may influence TEM1-targeted therapy efficacy

  • Development of threshold values for patient stratification

Research has demonstrated that TEM1 expression levels vary significantly across cancer types, with notable upregulation in various sarcomas, breast cancers showing correlation with lymph node metastasis and mortality, and expression in ovarian cancer microenvironment . These expression patterns may serve as the foundation for patient selection in clinical trials of TEM1-targeted therapeutics.

What are common technical challenges when working with TEM1 antibodies and how can they be addressed?

Researchers frequently encounter several technical challenges when working with TEM1 antibodies, each requiring specific troubleshooting approaches:

• Non-specific binding in immunohistochemistry/immunofluorescence:

  • Problem: Background staining in TEM1-negative tissues

  • Solutions:

    • Implement more stringent blocking (5% BSA, 5% normal serum, 0.3% Triton X-100)

    • Titrate antibody concentration to optimal signal-to-noise ratio

    • Pre-absorb antibody with tissues known to cause cross-reactivity

    • Use monovalent Fab fragments to reduce Fc-mediated binding

    • Include TEM1 knockout tissues as negative controls

• Variable antibody performance across applications:

  • Problem: Antibody works for ELISA but not Western blot

  • Solutions:

    • Verify epitope integrity under denaturation conditions

    • Test multiple antibody clones targeting different epitopes

    • For Western blots, modify lysis conditions to preserve epitope structure

    • Consider native vs. reducing conditions based on epitope location

• Species cross-reactivity issues:

  • Problem: Inconsistent performance between human and mouse models

  • Solutions:

    • Select antibodies validated for cross-reactivity (e.g., scFv78 derivatives)

    • Verify sequence homology at epitope regions

    • Consider species-specific antibodies for applications requiring absolute specificity

    • Validate using recombinant proteins from all target species

• Limited antibody stability:

  • Problem: Loss of binding activity during storage/handling

  • Solutions:

    • Conduct formal stability studies at different temperatures (4°C, -20°C, -80°C)

    • Add stabilizers appropriate for antibody format (e.g., glycerol, BSA)

    • Aliquot to avoid freeze-thaw cycles

    • For Fc-fusion proteins, verify glycosylation patterns affecting stability

• Inconsistent staining patterns:

  • Problem: Variable results across different tissue samples

  • Solutions:

    • Standardize fixation protocols (time, fixative composition)

    • Optimize antigen retrieval for each tissue type

    • Include positive control tissues in each experiment

    • Develop quantitative assessment methods to normalize across batches

How can researchers optimize TEM1 antibody production and purification for research applications?

Optimizing production and purification of TEM1 antibodies requires attention to several critical parameters:

• Expression system selection and optimization:

  • Mammalian expression (HEK293, CHO cells):

    • Ideal for maintaining proper glycosylation patterns

    • Codon optimization to improve expression efficiency (target CAI score ≥0.96)

    • Consider stable cell line development for consistent large-scale production

    • Evaluate serum-free media formulations to simplify downstream purification

  • Alternative systems:

    • Insect cells for high-yield production of non-glycosylated formats

    • Bacterial systems for scFv and other non-glycosylated fragments

    • Cell-free systems for rapid small-scale production

• Purification strategy development:

  • Affinity chromatography:

    • Protein A/G for Fc-containing formats

    • Immobilized metal affinity chromatography (IMAC) for His-tagged constructs

    • Antigen-specific affinity columns for highest purity requirements

  • Additional purification steps:

    • Size exclusion chromatography to remove aggregates and fragments

    • Ion exchange chromatography for charge variant separation

    • Endotoxin removal for in vivo applications

• Quality assessment metrics:

  • Purity analysis:

    • SDS-PAGE with both reducing and non-reducing conditions

    • Size exclusion HPLC for aggregate quantification

    • Mass spectrometry for molecular integrity verification

  • Functional testing:

    • Binding activity assays using SPR or cell-based methods

    • Thermal stability assessment using differential scanning fluorimetry

    • Freeze-thaw stability (≥5 cycles) to establish storage conditions

• Stability optimization:

  • Formulation development:

    • Buffer screening (pH 5.5-7.5 range)

    • Stabilizer addition (sucrose, trehalose, polysorbates)

    • Concentration optimization to balance stability and application needs

  • Storage condition validation:

    • Real-time and accelerated stability studies

    • Functionality testing after storage at different temperatures

    • Development of lyophilization protocols for long-term stability

For 78Fc and similar constructs, improving HEK cell expression yield and purification efficiency has been achieved through codon optimization, achieving a CAI score of 0.96, which significantly enhances production for research applications .

What analytical methods are recommended for assessing TEM1 antibody quality and lot-to-lot consistency?

Implementing robust analytical methods is essential for ensuring TEM1 antibody quality and consistency:

• Physicochemical characterization:

  • Size and purity analysis:

    • Size exclusion chromatography to quantify monomers, aggregates, fragments

    • SDS-PAGE with Coomassie and silver staining for purity assessment

    • Capillary electrophoresis for high-resolution analysis

    • Dynamic light scattering for particle size distribution

  • Structural integrity assessment:

    • Mass spectrometry for accurate molecular weight determination

    • Peptide mapping to confirm primary sequence

    • Circular dichroism for secondary structure evaluation

    • Differential scanning calorimetry for thermal stability profiles

• Functional characterization:

  • Binding assays:

    • Live-cell ELISA to determine apparent Kd values

    • Surface plasmon resonance for binding kinetics (kon/koff)

    • Flow cytometry with TEM1-expressing cells

    • Competition assays with reference standard antibody

  • Biological activity:

    • Cell-based functional assays relevant to application

    • Epitope binning to confirm consistent epitope targeting

    • Cross-reactivity assessment with related proteins

• Stability-indicating methods:

  • Accelerated stability studies:

    • Exposure to elevated temperatures (37°C, 40°C)

    • Mechanical stress testing (agitation, freeze-thaw cycles)

    • pH extremes to identify degradation patterns

    • Photo-stability assessment

  • Real-time monitoring:

    • Periodic testing of retained samples

    • Development of stability-indicating chromatographic methods

    • Monitoring critical quality attributes over shelf life

• Reference standard program:

  • Internal reference standard establishment:

    • Large-scale production of well-characterized reference lot

    • Comprehensive characterization using orthogonal methods

    • Long-term stability monitoring program

  • Comparative analysis:

    • Side-by-side testing of new lots against reference standard

    • Statistical methods to establish acceptance criteria

    • Trend analysis across multiple production lots

For 78Fc and other TEM1 antibody derivatives, specific quality indicators include thermal stability in physiological conditions, maintained binding capacity after serum exposure (72 hours at 37°C), and consistent sub-nanomolar binding affinity to cell-surface TEM1 .